Clinical Trial of BT02 in Patients With Advanced Solid Tumors - Trial NCT06404905
Access comprehensive clinical trial information for NCT06404905 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 1
Jan 24, 2024
Dec 31, 2024
Primary Outcome
Dose Limiting Toxicity,Incidence and severity of adverse events (AEs) and serious adverse events (SAEs),Maximum tolerated dose
Summary
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability,
 Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with
 Advanced Solid Tumors
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06404905
Non-Device Trial